Morgan Stanley analyst James Faucette raised the firm’s price target on Accenture to $335 from $300 and keeps an Equal Weight rating on the shares. Continued momentum in the Health & Public Service vertical give management confidence in reaching the higher end of the company’s 0-3% year-over-year constant currency organic growth guidance, leading to “better-than-feared” FY25 organic growth commentary, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACN:
- Mondelez collaborates with Accenture, Publicis Groupe on global marketing
- Mondelez to partner with Accenture and Publicis on AI marketing capabilities
- Accenture price target raised to $375 from $340 at Stifel
- Accenture upgraded to Overweight at Piper on ‘attractive’ FY25 set-up
- Accenture upgraded to Outperform from Neutral at Piper Sandler